# A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma

> **NCT02234986** · PHASE2 · COMPLETED · sponsor: **CASI pharmaceuticals, Inc.** · enrollment: 35 (actual)

## Conditions studied

- Advanced Adult Hepatocellular Carcinoma
- Advanced Fibrolamellar Carcinoma

## Interventions

- **DRUG:** ENMD-2076

## Key facts

- **NCT ID:** NCT02234986
- **Lead sponsor:** CASI pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2018-06-30
- **Final completion:** 2018-06-30
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02234986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02234986, "A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02234986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*